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We investigated the relation of overweight and obesity with cancer in a population-based cohort of more than 145000 Austrian
adults over an average of 9.9 years. Incident cancers (n¼6241) were identified through the state cancer registry. Using Cox
proportional-hazards models adjusted for smoking and occupation, increases in relative body weight in men were associated with
colon cancer (hazard rate (HR) ratio 2.48; 95% confidence interval (CI): 1.15, 5.39 for body mass index (BMI) X35kgm
 2) and
pancreatic cancer (HR 2.34, 95% CI: 1.17, 4.66 for BMI430kgm
 2) compared to participants with normal weight (BMI 18.5–
24.9kgm
 2). In women, there was a weak positive association between increasing BMI and all cancers combined, and strong
associations with non-Hodgkin’s lymphomas (HR 2.86, 95% CI: 1.49, 5.49 for BMIX30kgm
 2) and cancers of the uterine corpus (HR
3.93, 95% CI: 2.35, 6.56 for BMIX35kgm
 2). Incidence of breast cancer was positively associated with high BMI only after age 65
years. These findings provide further evidence that overweight is associated with the incidence of several types of cancer.
British Journal of Cancer (2005) 93, 1062–1067. doi:10.1038/sj.bjc.6602819 www.bjcancer.com
Published online 18 October 2005
& 2005 Cancer Research UK
Keywords: obesity; breast cancer; colonic cancer; endometrial cancer; lymphoma; non-Hodgkin; pancreatic cancer
                                            
Overweight and obesity is an increasing health problem, not only
for industrialised countries but also for most other parts of the
world. This epidemic appears to be affecting all ages, including
childhood (WHO, 2000). Prospective studies have observed an
association between overweight and overall mortality (Lew and
Garfinkel, 1979; Manson et al, 1995; Calle et al, 1999), and
several adverse health consequences of elevated body weight
are well established, including type II diabetes, hypertension and
coronary heart disease (Must et al, 1999). Obesity has also been
associated with cancer incidence and mortality, and positive
associations between obesity and risks of specific cancers,
including endometrial and kidney cancer, are widely accepted
(Calle and Kaaks, 2004). Inconsistent evidence of associations
between other cancers and body weight may be due in part to small
sample sizes and misclassification of body weight in retrospective
studies. The relation between body mass index (BMI) and
incidence of different cancers as ascertained by population-based
cancer registries has been investigated by few studies (Moller et al,
1994; Wolk et al, 2001). We conducted a prospective investigation
of the association between overweight and the incidence of cancer
(overall and specific types) using data from the Vorarlberg cancer
registry and a population-based cohort of more than 145000
Austrian men and women followed for an average of nearly 10
years.
MATERIALS AND METHODS
Study population
The Vorarlberg Health Monitoring and Promotion Program
(VHM&PP) is carried out in Vorarlberg, the westernmost province
of Austria. It is performed routinely by the Agency of Social and
Preventive Medicine and covers all adults of the whole province.
The screening examination takes place in the practice of local
physicians; it includes a physical examination, a blood test and a
consultation with a doctor. Enrolment is voluntary and costs are
covered by the participant’s (compulsory) health insurance. More
than two-thirds of the adult population of the province (between
the age of 35 and 54 years) participated and underwent at least one
examination since the beginning of the programme in 1985 (Ulmer
et al, 2004). The VHM&PP has been described in detail previously
(Ulmer et al, 2003).
Between 1985 and 2001, 167371 adult Vorarlberg residents were
enrolled in the VHM&PP Study Cohort after signing an informed
consent to store and process personal data (height, weight,
smoking and other factors). The current analysis was restricted
to participants with complete data on height, weight and
occupational group at enrolment. As in a previous study (Calle
et al, 2003), participants with a baseline BMI (kgm
 2) below
normal (BMIo18.5kgm
 2, n¼5053) were excluded. In order to
avoid an influence of cancer growth on body weight, participants
were further excluded if they had been diagnosed with a malignant
cancer prior to enrolment, or within 1 year following enrolment
(n¼1831). Therefore, the first year of follow-up time was not
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of less than 1 year (n¼5528) were excluded. To evaluate the
sensitivity of our analyses to this 1-year exclusion, we also repeated
the analyses with a 3-year exclusion. The final study cohort
consisted of 67447 men and 78484 women, with mean age at study
entry of 41.8 years for men and 42.5 years for women (Table 1).
The average time of follow-up was nearly 10 years, with a total of
1.45 million person-years. By the end of the total observation
period of 17 years, 6241 incident cancers (other than nonmelanoma
skin cancer) had been diagnosed (Table 1).
Body mass index
Baseline height and weight were recorded by medical staff at
enrolment during the VHM&PP physical examination. BMI was
classified according to World Health Organisation guidelines as
normal (18.50–24.99kgm
 2), overweight (25.00–29.99kgm
 2),
obese class I (30.00–34.99kgm
 2), and obese class II and III
(X35.00kgm
 2) (2000). Normal BMI was the reference category
for all analyses, and obesity categories were combined when
necessary to ensure a minimum of five cancer outcomes in each
exposure group.
Covariates
Associations were adjusted for smoking by including variables for
current smoking and former smoking in the model, with the
reference group being never smokers. Persons with missing
smoking values were classified as never smokers because baseline
questionnaire data did not differentiate between never-smokers
and participants with missing values. However, smoking informa-
tion from follow-up visits was available to validate the baseline
smoking status of more than 70% of study participants. Occupa-
tional group (blue collar, white collar or self-employed) was
determined by the insurance number of participants and was
included in the models as a surrogate measure of socioeconomic
status. Participants who were retired at baseline were classified
according to their former occupation, and housewives according to
their husband’s occupation.
End points
Between 1985 and 2002, incident invasive cancers were identified
by the Vorarlberg cancer registry, which is accepted for publica-
tion by the International Agency for Research on Cancer (IARC)
since 1993 (Parkin et al, 2003). The proportion of cancers
discovered by death certificate only (DCO) in the Vorarlberg
registry for cases diagnosed between 1993 and 1997 was 7% for
men and 9% for women (Oberaigner et al, 2003), and for cases
diagnosed between 1998 and 2002 about 5% in both sexes (W
Oberaigner, personal communication, Cancer Registry of Tyrol).
Nearly all cancers were histologically verified and coded according
to the ninth revision of the International Classification of Diseases
(ICD-9). Cohort data were linked with the Vorarlberg Death Index
to identify deaths among cohort members to calculate person-
years at risk.
Statistical analysis
We used Cox proportional-hazards models to compute hazard rate
ratios (HR) and 95% confidence intervals (95% CI) for overweight
and obesity relative to normal BMI, adjusted for smoking and
occupational group at baseline. The models included age (in single
years) in the strata statement. In tests of linear trend by BMI, the
median value for BMI within each interval was entered in a
regression model, and the significance of the term tested by the
Wald’s w
2 test. All calculations were carried out with SAS version
8.2 software.
All analyses were performed separately for men and women.
Analyses on specific cancers were restricted to those types of
cancer with at least 50 cases in men or women.
RESULTS
The study cohort consisted of 67447 men and 78484 women
(Table 1). In men, positive linear trends in cancer incidence with
increasing BMI were observed for colon and pancreatic cancer
(Table 2). In comparison to men with normal weight, the hazard
ratios for colon cancer were 1.56 (95% CI: 1.06, 2.30) for men with
BMI 30.0–34.99kgm
 2, and 2.48 (1.15, 5.39) for BMI 35.0kgm
 2
or more. The hazard ratios for men with BMI of at least
30.0kgm
 2 were for rectal cancer 1.66 (1.00, 2.73) and for
pancreatic cancer 2.34 (1.17, 4.66). Nonsignificant positive
associations were found for kidney and liver cancers.
In women, there was a weak positive association between BMI
and all cancers (Table 3). Endometrial (uterine corpus) cancer was
strongly associated with obesity class I (hazard ratio 2.13 (1.38,
3.27)) and obesity class II and III (hazard ratio 3.93 (2.35, 6.56)) in
comparison to normal weight. Furthermore, a positive association
was found between obesity and the incidence of non-Hodgkin’s
lymphomas (NHL) (hazard ratio 2.86 (1.49, 5.49), with a BMI of at
least 30.0kgm
 2). Kidney cancer was associated with overweight,
though not statistically significant. In contrast to men, BMI was
not associated with colon or rectal cancer in women.
Table 1 Characteristics of the VHM&PP study cohort
Men Women All
Eligible VHM&PP participants (N)
a 67447 78484 145931
Age at entry (years)
Mean (s.d.
b) 41.78 (14.47) 42.48 (15.66) 42.16 (15.12)
Range 18.66–93.03 19.00–94.13 18.66–94.13
Years of follow-up
Mean (s.d.
b) 9.63 (4.63) 10.18 (4.56) 9.93 (4.60)
Range 0.00–16.89 0.00–16.84 0.00–16.89
Total person-years at risk 649358 799122 1448480
BMI
c (%)
Normal: 18.5–24.9kgm
 2 50.47 62.86 57.13
Overweight: 25–29.9kgm
 2 40.05 25.60 32.28
Obese I: 30–34.9kgm
 2 8.23 8.55 8.40
Obese II and III: X35kgm
 2 1.25 2.99 2.19
Smoking (%)
Current smoker 29.99 20.78 25.03
Former smoker 13.27 4.99 8.79
Occupational group
d (%)
Blue collar 37.29 38.09 37.72
White collar 51.99 54.08 53.12
Self-employed 10.72 7.82 9.16
Number of cancers 3337 2904 6241
Age at cancer diagnosis (years)
Mean (s.d.
b) 65.34 (11.49) 62.88 (13.21) 64.20 (12.38)
Range 22.87–95.69 22.43–96.29 22.43–96.29
VHM&PP¼Vorarlberg Health Monitoring and Promotion Program; BMI¼body
mass index.
aEligible participants were enrolled between 1985 and 2001, had
complete baseline data for BMI, smoking and occupational group, and had no history
of malignant cancer prior to or within 1 year after baseline. Participants with
nonmelanoma skin cancer were excluded.
bs.d.: standard deviation.
cBMI: body mass
index (kgm
 2) based on height and weight measured at baseline physical
examination.
dOccupational group classified according to insurance number for
occupation at baseline, prior occupation (for pensioners) or husband’s occupation
(for housewives).
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and BMI overall. However, breast cancer diagnosed in women aged
65 years or older was positively associated with BMI (hazard ratios
1.48 (1.12, 1.95) for obesity class I and 1.29 (0.79, 2.11) for obesity
class II and III; P for trend 0.02).
All associations that were statistically significant after exclusion
of the first year following entry into the study remained unchanged
in terms of statistical significance when reanalysed excluding the
first 3 years.
DISCUSSION
The major strengths of our study are the prospective design, the
large number of subjects, the coverage of incident cases and the
length of follow-up. The population of Vorarlberg is culturally and
ethnically rather homogenous, with more than 90% of Austrian
origin (Ulmer et al, 2003). Body mass index was based on height
and weight measured at initial physical examination. Incident
cancers were ascertained by the population-based cancer registry
Table 2 Estimated HR and 95% CI for incident cancers diagnosed among male participants in the VHM&PP Study Cohort 1985–2001, according to BMI
at enrolment
BMI (kgm
 2)
a
18.5–24.9 25–29.9 30–34.9 X35
Type of cancer Normal Overweight Obese I Obese II and III
Number of persons/py
b 34040/330040 27012/262144 5552/50385 843/6788 P for trend
All cancers
Incident cases/py
b 1364/10293 1591/12078 342/2459 40/259
HR (95% CI)
c 1.00 0.97 (0.91–1.05) 0.96 (0.85–1.08) 0.94 (0.69–1.29) 0.37
Stomach cancer (ICD-9 151)
Incident cases/py
b 58/400 75/546 13/67
HR (95% CI)
c 1.00 1.04 (0.73–1.47) 0.72
a (0.40–1.33) 0.44
Colon cancer (ICD-9 153)
Incident cases/py
b 86/663 128/942 39/275 7/44
HR (95% CI)
c 1.00 1.14 (0.86–1.50) 1.56 (1.06–2.30) 2.48 (1.15–5.39) 0.005
Rectal cancer (ICD-9 154)
Incident cases/py
b 45/327 69/499 24/163
HR (95% CI)
c 1.00 1.20 (0.82–1.75) 1.66
a (1.01–2.73) 0.053
Liver cancer (ICD-9 155)
Incident cases/py
b 18/128 29/197 10/92
HR (95% CI)
c 1.00 1.32 (0.73–2.37) 1.67
a (0.75–3.72) 0.19
Pancreatic cancer (ICD-9 157)
Incident cases/py
b 19/129 31/250 14/109
HR (95% CI)
c 1.00 1.29 (0.73–2.27) 2.34
a (1.17–4.66) 0.02
Lung cancer (ICD-9 162)
Incident cases/py
b 209/1427 198/1288 50/308 7/32
HR (95% CI)
c 1.00 0.80 (0.66–0.97) 0.88 (0.65–1.20) 0.88 (0.41–1.86) 0.15
Melanoma (ICD-9 172)
Incident cases/py
b 59/373 56/409 7/48
HR (95% CI)
c 1.00 1.00 (0.68–1.46) 0.59
a (0.27–1.31) 0.32
Prostate cancer (ICD-9 185)
Incident cases 446/4001 583/5165 99/766 10/88
HR (95% CI)
c 1.00 1.03 (0.91–1.17) 0.82 (0.66–1.03) 0.73 (0.39–1.37) 0.16
Bladder cancer (ICD-9 188)
Incident cases/py
b 78/522 78/507 19/136
HR (95% CI)
c 1.00 0.81 (0.59–1.11) 0.74
a (0.45–1.22) 0.15
Kidney cancer (ICD-9 189)
Incident cases/py
b 46/356 70/486 21/162
HR (95% CI)
c 1.00 1.19 (0.82–1.74) 1.46
a (0.87–2.46) 0.14
Non-Hodgkin’s lymphoma (ICD-9 200+202)
Incident cases/py
b 31/236 45/288 8/54
HR (95% CI)
c 1.00 1.26 (0.80–2.01) 0.91
a (0.41–1.99) 0.86
VHM&PP¼Vorarlberg Health Monitoring and Promotion Program; HR¼hazards ratio; CI¼confidence interval; ICD¼International Classification of Diseases; BMI¼body mass
index.
aObese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.
bPerson-years.
cThe Cox proportional-hazards model was
stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.
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yTable 3 Estimated HR and 95% CI for incident cancers diagnosed among female participants in the VHM&PP Study Cohort 1985–2001, according to
BMI at enrolment
BMI (kgm
 2)
a
Type of cancer 18.5–24.9 25–29.9 30–34.9 X35
Number of persons/py
b 49336/502849 20090/208574 6709/66351 2349/21349 P for trend
All cancers
Incident cases/py
b 1425/10712 997/6883 369/2493 113/795
HR (95% CI)
c 1.00 1.05 (0.96–1.14) 1.16 (1.03–1.30) 1.18 (0.97–1.43) 0.008
Stomach cancer (ICD-9 151)
Incident cases/py
b 56/394 36/212 20/146 6/45
HR (95% CI)
c 1.00 0.78 (0.51–1.20) 1.28 (0.76–2.15) 1.34 (0.57–3.13) 0.48
Colon cancer (ICD-9 153)
Incident cases/py
b 122/958 106/773 35/238 8/82
HR (95% CI)
c 1.00 1.13 (0.86–1.47) 1.11 (0.76–1.62) 0.88 (0.43–1.81) 0.73
Rectal cancer (ICD-9 154)
Incident cases/py
b 68/504 48/315 12/100 5/27
HR (95% CI)
c 1.00 0.90 (0.62–1.31) 0.66 (0.36–1.23) 0.96 (0.38–2.39) 0.32
Pancreatic cancer (ICD-9 157)
Incident cases/py
b 29/231 21/154 15/80
HR (95% CI)
c 1.00 0.87 (0.49–1.53) 1.42
a (0.76–2.68) 0.4
Lung cancer (ICD-9 162)
Incident cases/py
b 64/513 45/300 17/97
HR (95% CI)
c 1.00 1.00 (0.68–1.48) 0.87
a (0.50–1.50) 0.67
Melanoma (ICD-9 172)
Incident cases/py
b 79/535 38/268 13/77
HR (95% CI)
c 1.00 1.03 (0.68–1.54) 0.86
a (0.47–1.57) 0.72
Breast cancer (ICD-9 174)
Incident cases/py
b 551/4162 335/2326 123/860 36/270
HR (95% CI)
c 1.00 0.96 (0.83–1.10) 1.07 (0.88–1.31) 1.01 (0.72–1.42) 0.8
Cervical cancer (ICD-9 180)
Incident cases/py
b 41/205 17/106 6/43
HR (95% CI)
c 1.00 0.85 (0.47–1.54) 0.69
a (0.29–1.66) 0.37
Cancer of the uterine corpus (ICD-9 182)
Incident cases/py
b 63/452 59/441 33/230 20/93
HR (95% CI)
c 1.00 1.29 (0.90–1.86) 2.13 (1.38–3.27) 3.93 (2.35–6.56) o0.001
Ovarian cancer (ICD-9 183)
Incident cases/py
b 61/490 39/245 21/141
HR (95% CI)
c 1.00 1.03 (0.68–1.56) 1.25
a (0.75–2.08) 0.44
Bladder cancer (ICD-9 188)
Incident cases/py
b 21/128 22/120 11/85
HR (95% CI)
c 1.00 1.35 (0.74–2.48) 1.60
a (0.76–3.36) 0.19
Kidney cancer (ICD-9 189)
Incident cases/py
b 32/290 44/299 12/77
HR (95% CI)
c 1.00 1.81 (1.13–2.89) 1.14
a (0.58–2.24) 0.3
Thyroid cancer (ICD-9 193)
Incident cases/py
b 29/173 24/183 8/52
HR (95% CI)
c 1.00 1.45 (0.82–2.58) 1.18
a (0.53–2.65) 0.44
Non-Hodgkin’s lymphoma (ICD-9 200+202)
Incident cases/py
b 22/154 24/170 18/126
HR (95% CI)
c 1.00 1.64 (0.89–3.01) 2.86
a (1.49–5.49) 0.002
VHM&PP¼Vorarlberg Health Monitoring and Promotion Program; HR¼hazards ratio; CI¼confidence interval; ICD¼International Classification of Diseases; BMI¼body mass
index.
aObese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.
bPerson-years.
cThe Cox proportional-hazards model was
stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.
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and outcome misclassification was therefore low.
The limitations of our study include that, despite the overall size
of the cohort, some cancers of interest (for example, oesophageal
adenocarcinoma or gallbladder cancer) could not be evaluated due
to small numbers of cases. In addition, the prevalence of obesity in
our cohort was relatively low. Consequently the power to examine
extreme levels of obesity, particularly in association with less
common cancers, was limited. The high proportion of never-
smoking patients with lung cancer (31%) suggests that there was
some misclassification of smoking status, although this would
probably attenuate the relation between BMI and most cancers,
given the inverse association between smoking and body weight.
We used occupational group as a rough surrogate for socio-
economic status, but were unable to account for such potentially
confounding factors as alcohol consumption or physical activity.
Our finding of an association between BMI and both colon and
rectum cancers in men supports earlier observations (Lew and
Garfinkel, 1979; Giovannucci et al, 1995; Pan et al, 2004; Samanic
et al, 2004) and may be due to the growth-promoting effects of
insulin and insulin-like growth factor (IGF-1), both increased in
obesity (Calle and Kaaks, 2004). Our failure to find an association
between BMI and colon cancer in women also agrees with other
studies (Phillips and Snowdon, 1985; Shimizu et al, 2003), and may
be related to the protective effects of elevated oestrogen levels in
overweight postmenopausal women, as found by studies of
exogenous hormone therapy in such women (Calle et al, 1995;
Newcomb and Storer, 1995).
We observed a positive association between pancreatic cancer
and overweight or obesity in men, and to a lesser extent in women.
Other studies have been inconsistent in this connection (Berrington
et al, 2003). As with colon cancer, relations between pancreatic
cancer and BMI have been attributed to the growth-promoting
effects of elevated insulin and IGFs secondary to obesity (Takeda
and Escribano, 1991), although the carcinogenic effects of insulin
have also been proposed to explain positive associations with
abnormal glucose metabolism (Gapstur et al, 2000) or diabetes
mellitus (Everhart and Wright, 1995).
In line with previous reports (Yuan et al, 1998; Chow et al,
2000), we observed a positive relation between BMI and incidence
of kidney cancer in men, which, however, did not reach statistical
significance. In women, our findings showed a positive association
between kidney cancer and overweight, but not obesity. Our
finding of a positive association between BMI and breast cancer
only among women at the age of 65 years or older is consistent
with previous reports (Hunter and Willett, 1993).
A relation between endometrial cancer (cancer of the uterine
corpus) and overweight is widely accepted (Calle and Kaaks, 2004),
and it was found that this in very obese women (BMIX35kgm
 2)
were more likely to be diagnosed with endometrial cancer than
women with normal BMI at baseline (HR 3.93, 95% CI: 2.35, 6.56).
A crucial pathway seems to be oestrogens that are not counter-
balanced by progesterone (the ‘unopposed oestrogen’ hypothesis)
(Kaaks et al, 2002). Anovulatory cycles in obese premenopausal
women may contribute to a deficiency of progesterone, which
normally opposes the mitogenic effect of oestrogen on the
endometrial mucosa.
We also observed a strong positive association between BMI and
NHL among women, but not men. Previous prospective studies of
overweight and NHL have been inconsistent (Moller et al, 1994;
Wolk et al, 2001; Cerhan et al, 2002; Calle et al, 2003; Samanic et al,
2004), though several case–control studies have reported an
association between overweight and NHL in both sexes (Holly
et al, 1999; Pan et al, 2004; Skibola et al, 2004). The incidence of
NHL has increased in many parts of the world (Muller et al, 2005)
and obesity might be a contributing factor.
As previously reported (Calle and Kaaks, 2004), liver cancer
showed a (non-significant) association with BMI in men with point
estimates clearly above one, but based on only 57 cases; there were
too few cases of liver cancer for a separate analysis in women.
Many studies have examined relations between overweight and
single cancer outcomes. Few prospective studies examined the
influence of overweight on a range of specific cancers both in men
and women (Lew and Garfinkel, 1979; Moller et al, 1994; Wolk
et al, 2001; Calle et al, 2003). Our study of a large Austrian cohort
provides additional support from another population for associa-
tions between BMI and the incidence of colon, rectal and
pancreatic cancer, and to a lesser extent of kidney and liver
cancer in men, and with endometrial cancer, postmenopausal
breast cancer and NHL in women.
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